Chey WD, Leontiadis GI, Howden CW, Moss
SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J
Gastroenterol 2017;112(2):212-39. https://www.ncbi.nlm.nih.gov/pubmed/28071659
Fallone CA, Chiba N, van Zanten SV,
Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment
of Helicobacter pylori infection in adults. Gastroenterology 2016;151(1):51-69
e14. https://www.ncbi.nlm.nih.gov/pubmed/27102658
Fock KM, Katelaris P, Sugano K, Ang TL,
Hunt R, Talley NJ, et al. Second Asia-Pacific consensus guidelines for
Helicobacter pylori infection. Journal of Gastroenterology and Hepatology
2009;24(10):1587-600. https://www.ncbi.nlm.nih.gov/pubmed/19788600
Ford AC, Forman D, Hunt R, Yuan Y,
Moayyedi P. Helicobacter pylori eradication for the prevention of gastric
neoplasia. Cochrane Database Syst Rev 2015;(7):CD005583. https://www.ncbi.nlm.nih.gov/pubmed/26198377
Jones NL, Koletzko S, Goodman K, Bontems
P, Cadranel S, Casswall T, et al. Joint ESPGHAN/NASPGHAN guidelines for the
management of Helicobacter pylori in children and adolescents (update 2016). J
Pediatr Gastroenterol Nutr 2017;64(6):991-1003. https://www.ncbi.nlm.nih.gov/pubmed/28541262
Kang JM, Kim N, Lee DH, Park YS, Kim YR,
Kim JS, et al. Second-line treatment for Helicobacter pylori infection: 10-day
moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter
2007;12(6):623-8. https://www.ncbi.nlm.nih.gov/pubmed/18001404
Malfertheiner P, Megraud F, O'Morain CA,
Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori
infection-the Maastricht V/Florence Consensus Report. Gut 2017;66(1):6-30. https://www.ncbi.nlm.nih.gov/pubmed/27707777
Mitchell H, Katelaris P. Epidemiology,
clinical impacts and current clinical management of Helicobacter pylori
infection. Med J Aust 2016;204(10):376-80. https://www.ncbi.nlm.nih.gov/pubmed/27256648
Nyssen OP, McNicholl AG, Megraud F,
Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple
first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst
Rev 2016;(6):CD009034. https://www.ncbi.nlm.nih.gov/pubmed/27351542
Rakici H, Ayaz T, Akdogan RA, Bedir R.
Comparison of levofloxacin- and moxifloxacin-based triple therapies with
standard treatment in eradication of Helicobacter pylori as first-line therapy.
Digestion 2014;90(4):261-4. https://www.ncbi.nlm.nih.gov/pubmed/25547786
Rawla P, Barsouk A. Epidemiology of
gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol
2019;14(1):26-38. https://www.ncbi.nlm.nih.gov/pubmed/30944675
Schubert JP, Warner MS, Rayner CK,
Roberts-Thomson IC, Mangoni AA, Costello S, et al. Increasing Helicobacter
pylori clarithromycin resistance in Australia over 20 years. Intern Med J 2021.
https://www.ncbi.nlm.nih.gov/pubmed/34865299
Sugano K, Tack J, Kuipers EJ, Graham DY,
El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori
gastritis. Gut 2015;64(9):1353-67. https://www.ncbi.nlm.nih.gov/pubmed/26187502
Yuan Y, Ford AC, Khan KJ, Gisbert JP,
Forman D, Leontiadis GI, et al. Optimum duration of regimens for Helicobacter
pylori eradication. Cochrane Database Syst Rev 2013;(12):CD008337. https://www.ncbi.nlm.nih.gov/pubmed/24338763
